이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Alaunos Therapeutics 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

NasdaqCM:TCRT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2024	0	-27	-23	-23	N/A
12/31/2023	0	-35	-30	-30	N/A
9/30/2023	0	-36	-30	-30	N/A
6/30/2023	3	-37	-30	-30	N/A
3/31/2023	3	-38	-31	-31	N/A
12/31/2022	3	-38	-29	-29	N/A
9/30/2022	3	-40	-38	-37	N/A
6/30/2022	0	-54	-41	-41	N/A
3/31/2022	0	-67	-57	-54	N/A
12/31/2021	0	-79	-65	-61	N/A
9/30/2021	0	-90	-70	-63	N/A
6/30/2021	N/A	-87	-78	-70	N/A
3/31/2021	N/A	-83	-72	-62	N/A
12/31/2020	N/A	-80	-67	-57	N/A
9/30/2020	N/A	-73	-58	-52	N/A
6/30/2020	N/A	-127	-51	-46	N/A
3/31/2020	N/A	-123	-41	-41	N/A
12/31/2019	N/A	-118	-41	-41	N/A
9/30/2019	N/A	92	-41	-41	N/A
6/30/2019	N/A	148	-39	-39	N/A
3/31/2019	N/A	145	-41	-41	N/A
12/31/2018	0	137	-50	-49	N/A
9/30/2018	2	-76	-51	-50	N/A
6/30/2018	3	-75	-55	-54	N/A
3/31/2018	5	-75	-60	-59	N/A
12/31/2017	6	-73	N/A	-55	N/A
9/30/2017	6	-70	N/A	-56	N/A
6/30/2017	6	-67	N/A	-57	N/A
3/31/2017	6	-180	N/A	-57	N/A
12/31/2016	7	-172	N/A	-58	N/A
9/30/2016	7	-167	N/A	-69	N/A
6/30/2016	7	-171	N/A	-10	N/A
3/31/2016	6	-54	N/A	-6	N/A
12/31/2015	4	-120	N/A	0	N/A
9/30/2015	3	-121	N/A	14	N/A
6/30/2015	2	-109	N/A	-42	N/A
3/31/2015	1	-100	N/A	-38	N/A
12/31/2014	1	-32	N/A	-37	N/A
9/30/2014	1	-30	N/A	-36	N/A
6/30/2014	1	-41	N/A	-41	N/A
3/31/2014	1	-54	N/A	-50	N/A
12/31/2013	1	-57	N/A	-60	N/A
9/30/2013	1	-78	N/A	-72	N/A

애널리스트 미래 성장 예측

수입 대 저축률: TCRT 의 예상 수익 증가율이 절약률( 2.4% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: TCRT 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: TCRT 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: TCRT 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: TCRT 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: TCRT 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Alaunos Therapeutics 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Forecast to breakeven in 2025

Price target decreased to US$3.75

Price target increased to US$4.20

Price target decreased to US$3.70

Consensus forecasts updated

Consensus forecasts updated

Recent updates

Alaunos Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Alaunos Therapeutics, Inc. Appoints Dale Curtis Hogue, Jr. as Interim Chief Executive Officer

Alaunos Therapeutics, Inc. Appoints Dale Curtis Hogue as Director

Alaunos Therapeutics, Inc. Announces the Resignation of Mary Thistle as Member of the Board of Directors

Alaunos Therapeutics Receives a Staff Delisting Determination Letter from the Listing Qualifications Department

Nasdaq Approves Transfer of the Listing of the Common Stock of Alaunos Therapeutics from the Nasdaq Global Select Market to the Nasdaq Capital Market

Alaunos Therapeutics Announces Presentation At the 2Nd Hawaii Global Summit on Thoracic Malignancies

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

Alaunos Therapeutics, Inc. to Report Q1, 2023 Results on May 10, 2023

Forecast to breakeven in 2025

Price target decreased to US$3.75

Alaunos Therapeutics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Independent Director recently bought US$813k worth of stock

Alaunos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Alaunos Therapeutics, Inc. has completed a Follow-on Equity Offering.

High number of new and inexperienced directors

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Alaunos Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology

Alaunos Therapeutics, Inc. Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Alaunos posts 51% tumor reduction for lung cancer therapy

Alaunos sheds 52% ahead of data readout for T-cell therapy platform

Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using Its TCR-T Cell Therapy

Price target increased to US$4.20

Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data

Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02

Alaunos Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Price target decreased to US$3.70

Alaunos Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

Alaunos Therapeutics, Inc. Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors

High number of new and inexperienced directors

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

ZIOPHARM Oncology, Inc.(NasdaqGS:TCRT) dropped from NASDAQ Composite Index

Consensus forecasts updated

Consensus forecasts updated

ZIOPHARM Oncology, Inc. Announces Operational Progress

Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Price target decreased to US$4.60

High number of new directors

ZIOPHARM Oncology, Inc. announced delayed 10-Q filing

ZIOPHARM Oncology, Inc.(NasdaqGS:ZIOP) dropped from Russell 3000E Value Index

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

ZIOPHARM records sharpest gain in nearly four months

Chief Legal Officer & Secretary has left the company

Price target decreased to US$5.08

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

Price target decreased to US$5.08

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

CEO & Director Laurence James Cooper has left the company

Ziopharm Oncology, Inc. Receives IND Clearance by the U.S. FDA for Its TCR-T Trial Utilizing Six "Hotspot" TCRs from Its Library

Ziopharm Oncology, Inc. Appoints Timothy Cunningham Interim Chief Financial Officer

ZIOPHARM Oncology, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Ziopharm Oncology, Inc. Announces Election of Robert Postma to Board of Directors

New 90-day high: US$4.24

Ziopharm Oncology Inc. Announces Executive Changes

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

New 90-day high: US$3.16

CEO & Director notifies of intention to sell stock

Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

ZIOPHARM Oncology, Inc. Announces Executive Changes

Activist holder wins Ziopharm Oncology board seats

Ziopharm Oncology, Inc. Announces Resignation of Satyavrat Shukla as CFO

New 90-day high: US$3.09

Ziopharm Oncology CFO to step down